Monoclonal antibodies (mAbs) are laboratory-produced immunoglobulin molecules engineered to bind specific target antigens with high affinity and specificity, representing one of the most successful therapeutic classes in modern medicine. From their origins in hybridoma technology to advanced recombinant engineering, mAbs have become indispensable across oncology, immunology, infectious disease, and hematology.
What Are Monoclonal Antibodies?
Monoclonal antibodies are derived from a single B cell clone, ensuring uniform binding to a single epitope. Therapeutic mAbs are classified by their structure (full-length IgG, Fab fragments, bispecific, antibody-drug conjugates) and by their degree of human origin, which affects immunogenicity and pharmacokinetics.
Drug Classes and Mechanisms
Nomenclature indicates the origin of the antibody. Murine (-omab) antibodies are fully mouse-derived and highly immunogenic. Chimeric (-ximab) antibodies combine mouse variable regions with human constant regions. Humanized (-zumab) antibodies have mouse complementarity-determining regions grafted onto a human framework. Fully human (-umab) antibodies are generated from transgenic mice or phage display libraries, minimizing immunogenicity.
Mechanisms of action are diverse. Neutralizing antibodies block ligand-receptor interactions, such as adalimumab binding TNF-alpha. Receptor-blocking antibodies like trastuzumab prevent growth factor signaling. Antibody-dependent cellular cytotoxicity (ADCC) recruits immune effectors via the Fc region. Complement-dependent cytotoxicity (CDC) activates the classical complement pathway. Antibody-drug conjugates deliver cytotoxic payloads specifically to antigen-expressing cells.
Production initially used hybridoma technology, fusing immunized mouse B cells with myeloma cells. Current methods include recombinant DNA technology in CHO cell lines and phage display for fully human antibodies.
Therapeutic Uses
In oncology, rituximab (anti-CD20) revolutionized B cell lymphoma treatment. Trastuzumab (anti-HER2) transformed HER2-positive breast cancer prognosis. Cetuximab (anti-EGFR) is used in colorectal and head and neck cancers. Naked antibodies, antibody-drug conjugates (ado-trastuzumab emtansine), and bispecific T cell engagers (blinatumomab) represent expanding applications.
In autoimmune disease, anti-TNF agents (infliximab, adalimumab) treat rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Anti-IL-17 (secukinumab) and anti-IL-23 (ustekinumab) target psoriatic and rheumatologic diseases.
In infectious disease, palivizumab (anti-RSV) is used for prophylaxis in high-risk infants. Casirivimab and imdevimab are anti-SARS-CoV-2 spike protein antibodies.
In hematology, eculizumab (anti-C5) blocks complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Emicizumab (bispecific anti-factor IXa and X) prevents bleeding in hemophilia A.
Adverse Effects
Infusion reactions are the most common adverse effect, ranging from fever and chills to anaphylaxis. Cytokine release syndrome occurs with T cell-engaging antibodies. Immunogenicity can produce neutralizing anti-drug antibodies, reducing efficacy. Long-term immunosuppression increases infection risk with certain antibodies. Specific toxicities include progressive multifocal leukoencephalopathy with natalizumab and reactivation of tuberculosis with anti-TNF agents.
Key Clinical Considerations
Premedication reduces infusion reaction risk. Screening for latent tuberculosis is mandatory before anti-TNF therapy. Therapeutic drug monitoring is used for some mAbs to optimize dosing. Biosimilars have expanded access by providing lower-cost alternatives after patent expiry.
Conclusion
Monoclonal antibodies have transformed therapeutics across multiple disease areas, offering unprecedented target specificity. Advances in antibody engineering continue to produce novel formats with enhanced efficacy, reduced immunogenicity, and improved delivery characteristics.
